A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
- Registration Number
- NCT06401044
- Lead Sponsor
- Amgen
- Brief Summary
The primary objective of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses.
- Detailed Description
Recruitment has ended for the Phase 1 portion of the study and will reopen when Phase 2 begins recruitment.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part A: AMG 732 AMG 732 Participants in 6 cohorts will receive either AMG 732 or placebo in Single Ascending Doses (SAD). Part A: Placebo Placebo Participants in 6 cohorts will receive either AMG 732 or placebo in Single Ascending Doses (SAD).
- Primary Outcome Measures
Name Time Method Part A: Number of Participants With Treatment-emergent Adverse Events Day 1 through Week 36 (End of Study)
- Secondary Outcome Measures
Name Time Method Part A: Maximum Observed Plasma Concentration (Cmax) of AMG 732 Up to Week 36 Part A: Time to Cmax (Tmax) of AMG 732 Up to Week 36 Part A: Half-life (t1/2) of AMG 732 Up to Week 36 Part A: Area Under the Plasma Concentration-time Curve (AUC) of AMG 732 Up to Week 36
Trial Locations
- Locations (1)
Ppd Las Vegas Research Unit
🇺🇸Las Vegas, Nevada, United States